These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36200957)

  • 1. Adapting investigational drug services during a pandemic: Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group.
    Finnes HD; Child B; DeFrates S; Kinsman K; Thorne A; Lentz S; Lockhorst R; Murphy J; Urmanski A; Amin S; Barr H; Baviskar S; Beckman C; Chow N; Derba M; Erickson M; Hennes E; Heisey H; Lau R; Limvorasak S; Luckritz T; Mays T; Nzelibe CN; Romanowski T; Smith C; Tesoro D; Toeniskoetter K; Voytilla K
    Am J Health Syst Pharm; 2023 Jan; 80(1):e67-e73. PubMed ID: 36200957
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond.
    Aruru M; Truong HA; Clark S
    Res Social Adm Pharm; 2021 Jan; 17(1):1967-1977. PubMed ID: 32389631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the effects of a global pandemic on the operation of an investigational drug service.
    Coulter C; Thorne A; Amerine L
    Am J Health Syst Pharm; 2023 Apr; 80(9):e126-e130. PubMed ID: 36745616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computer-assisted investigational drug information and testing mechanism for nurses.
    Wermeling DP; Nowak-Rapp M; Sitzlar S
    Hosp Pharm; 1994 Aug; 29(8):745-6, 748-50. PubMed ID: 10135743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coping with the residency program during COVID-19: Hematology oncology pharmacy residents' perspective.
    AlAzmi AA; AlNajjar F; AlShomrani M
    J Oncol Pharm Pract; 2020 Dec; 26(8):1942-1946. PubMed ID: 33131451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States.
    Mahmoudjafari Z; Alexander M; Roddy J; Shaw R; Shigle TL; Timlin C; Culos K
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1043-1049. PubMed ID: 32305359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives of Oncology Nursing and Investigational Pharmacy in Oncology Research.
    Black L; Kulkarni D
    Semin Oncol Nurs; 2020 Apr; 36(2):151004. PubMed ID: 32265165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of conducting clinical trials of investigational medicinal products during a respiratory virus pandemic: Lessons learnt from COVID-19.
    Burns JE; Carlin FE
    Clin Trials; 2021 Apr; 18(2):260-262. PubMed ID: 33231098
    [No Abstract]   [Full Text] [Related]  

  • 9. A practical approach to assess the hazardous exposure potential of investigational drugs.
    McLeod EN; Fillis CJ; Blind JE
    Am J Health Syst Pharm; 2020 Apr; 77(9):697-700. PubMed ID: 34278414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational antiviral drugs for the treatment of COVID-19 patients.
    Beheshtirouy S; Khani E; Khiali S; Entezari-Maleki T
    Arch Virol; 2022 Mar; 167(3):751-805. PubMed ID: 35138438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical research: national survey of U.S. pharmacy-based investigational drug services--1997.
    Rockwell K; Bockheim-McGee C; Jones E; Kwon IW
    Am J Health Syst Pharm; 1999 Feb; 56(4):337-44. PubMed ID: 10690217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacy preparedness and response for the prevention and control of coronavirus disease (COVID-19) in Aksum, Ethiopia; a qualitative exploration.
    Kasahun GG; Kahsay GM; Asayehegn AT; Demoz GT; Desta DM; Gebretekle GB
    BMC Health Serv Res; 2020 Oct; 20(1):913. PubMed ID: 33008384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provision of clinical pharmacy services during the COVID-19 pandemic: Experiences of pharmacists from 16 European countries.
    Paudyal V; Cadogan C; Fialová D; Henman MC; Hazen A; Okuyan B; Lutters M; Stewart D
    Res Social Adm Pharm; 2021 Aug; 17(8):1507-1517. PubMed ID: 33288420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTSA pharmacies: Contribution to research and public health during the COVID-19 pandemic.
    MacArthur RB; Bentur OS; MacArthur IC; Bartoo AS; Capozzi DL; Christensen JA; Johnson AL; Patel K; Coller BS
    J Clin Transl Sci; 2021 Feb; 5(1):e108. PubMed ID: 34192062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abstracts of HOPA 2010, the Hematology Oncology Pharmacy Association Annual Meeting. March 24-27, 2010. New Orleans, Louisiana, USA.
    J Oncol Pharm Pract; 2010 Mar; 16(1 Suppl):5-17. PubMed ID: 20164168
    [No Abstract]   [Full Text] [Related]  

  • 17. A survey of pharmacy-coordinated investigational drug services.
    Cipywnyk DM; McBride J
    Can J Hosp Pharm; 1991 Aug; 44(4):183-8, 200. PubMed ID: 10112895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing oncology research protocols.
    Lunik MC
    Top Hosp Pharm Manage; 1994 Jul; 14(2):11-21. PubMed ID: 10136201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinay Prasad on the use of exaggerated language in cancer research, and how it can mislead doctors, patients, and the public.
    Prasad VK
    Oncology (Williston Park); 2016 Feb; 30(2):120-1. PubMed ID: 26888789
    [No Abstract]   [Full Text] [Related]  

  • 20. Providing Oncology Pharmacy Services During the Coronavirus Pandemic: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique [SFPO]) Guidelines.
    Pourroy B; Tournamille JF; Bardin C; Slimano F; Chevrier R; Rioufol C; Madelaine I
    JCO Oncol Pract; 2020 Nov; 16(11):e1282-e1290. PubMed ID: 32539650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.